Trial Profile
Randomized double-blind placebo-controlled prospective, parallel, multicentre clinical trial of bacterial polivalent vaccine (BACTEK) administered by sublingual mucosa in subjects with chronic obstructive pulmonary disease (COPD) for efficacy evaluation, security and immunomodulatory response
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs MV 130 (Primary) ; MV 130 (Primary)
- Indications Bacterial infections; Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Sponsors Inmunotek
- 04 May 2022 Planned End Date changed from 1 Mar 2022 to 1 Mar 2023.
- 04 May 2022 Planned primary completion date changed from 1 Mar 2022 to 1 Mar 2023.
- 01 Feb 2022 Planned End Date changed from 1 Dec 2020 to 1 Mar 2022.